Global Pediatric Neuroblastoma Treatment Market Size (2024 - 2029)

The pediatric neuroblastoma treatment market is expected to experience growth over the forecast period, driven by an increasing burden of pediatric neuroblastoma and enhanced research and development efforts. Despite the disruptions caused by the COVID-19 pandemic, which affected medical supply chains and treatment schedules, the market is poised for expansion due to government investments in research and development and increased public awareness of treatment options. However, the high costs and potential side effects of cancer therapies may pose challenges to market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Oncology Drugs Research Pediatric Neuroblastoma Treatment Industry Market Size

Market Size of Global Pediatric Neuroblastoma Treatment Industry

Pediatric Neuroblastoma Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 6.30 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Pediatric Neuroblastoma Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Pediatric Neuroblastoma Treatment Market Analysis

The pediatric neuroblastoma treatment market is projected to register a CAGR of nearly 6.3% over the forecast period.

The COVID-19 pandemic had a significant impact on both the global economy and healthcare infrastructure. The pediatric neuroblastoma treatment market was severely impacted due to a disruption in medical supplies and delayed fulfillment of neuroblastoma treatment medications and treatments. For instance, an article published in January 2021 in PubMed stated that there was a significant reduction in the daily mean number of pediatric patients undergoing chemotherapy, radiotherapy, surgery, and imaging studies during COVID-19. However, the market is anticipated to witness growth in the coming years due to the rise in the burden of pediatric neuroblastoma and the increase in research and development for pediatric neuroblastoma treatments.

According to a National Cancer Institute (NCI) November 2021 update, among children (ages 0 to 14 years), the most common types of cancer are leukemias, followed by brain and other CNS tumors, lymphomas, neuroblastoma, kidney tumors, and malignant bone tumors. As per the same source, in 2021, it was estimated that 15,590 children and adolescents ages 0 to 19 were likely to be diagnosed with cancer.

Additionally, the government's increased investments in R&D initiatives to build the pediatric medical infrastructure and the public's growing knowledge of pediatric neuroblastoma therapy are promoting market expansion. For instance, the Rally Foundation for Childhood Cancer Research granted USD 3.4 million in grants to Drs. Miller Huang and Satyaki Sengupta in March 2022 to study the role of chromosome 17q gain in neuroblastoma and Dr. Muxiang Zhou to find novel MYCN inhibitors of therapy for pediatric neuroblastoma, and other researchers.

On the other hand, the high cost and side effects associated with cancer therapy are likely to restrain the market growth over the forecast period.

Pediatric Neuroblastoma Treatment Industry Segmentation

As per the scope of the report, neuroblastoma is cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. Neuroblastoma is the most common extracranial solid tumor in childhood. 

The pediatric neuroblastoma treatment market is segmented by Treatment Type (Chemotherapy, Immunotherapy, and Others), Distribution Channel (Hospital Pharmacies and Retail Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Type
Chemotherpy
Immunotherapy
Other Treatment Types
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Pediatric Neuroblastoma Treatment Market Size Summary

The pediatric neuroblastoma treatment market is poised for significant growth, driven by an increasing incidence of the disease and advancements in research and development. The market experienced disruptions during the COVID-19 pandemic, which affected the supply chain and delayed treatments. However, the resurgence in research activities and government investments in pediatric medical infrastructure are expected to propel market expansion. Chemotherapy remains a cornerstone of treatment, often used in conjunction with other therapies like radiation and surgery, to manage symptoms and reduce disease spread. The effectiveness of chemotherapeutic agents and the rising prevalence of neuroblastoma in children are key factors contributing to the market's growth trajectory.

North America is anticipated to be a leading region in the pediatric neuroblastoma treatment market, supported by a robust healthcare infrastructure and favorable government policies. The United States, in particular, is expected to hold a significant market share due to its large patient population and advanced healthcare system. The market is characterized by moderate competition, with major players like United Therapeutics Corporation, APEIRON Biologics AG, and Pfizer, Inc. actively engaging in product launches, partnerships, and research investments to enhance their market presence. Regulatory approvals and strategic collaborations are further expected to broaden product portfolios and improve treatment outcomes, thereby driving market growth.

Explore More

Global Pediatric Neuroblastoma Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Burden Of Pediatric Neuroblastoma Coupled With Increasing R&D

      2. 1.2.2 Rise in Awareness of Available Treatment For Cancer

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost And Side Effects Associated With Cancer Therapy

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 2.1 By Treatment Type

      1. 2.1.1 Chemotherpy

      2. 2.1.2 Immunotherapy

      3. 2.1.3 Other Treatment Types

    2. 2.2 By Distribution Channel

      1. 2.2.1 Hospital Pharmacies

      2. 2.2.2 Retail Pharmacies

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Pediatric Neuroblastoma Treatment Market Size FAQs

The Global Pediatric Neuroblastoma Treatment Market is projected to register a CAGR of 6.30% during the forecast period (2024-2029)

Baxter International, United Therapeutics Corporation, APEIRON Biologics AG, Y-mAbs Therapeutics, Inc. and CELLECTAR BIOSCIENCES, INC. are the major companies operating in the Global Pediatric Neuroblastoma Treatment Market.

Pediatric Neuroblastoma Treatment Market Report Snapshots

Pediatric Neuroblastoma Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)